My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />J-4 <br /> <br /> <br />Schedule B <br />Approved Uses <br />Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder <br />or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs <br />or strategies that may include, but are not limited to, the following: <br />PART ONE: TREATMENT <br /> <br />A. TREAT OPIOID USE DISORDER (OUD) <br />Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance Use <br />Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or evidence- <br />informed programs or strategies that may include, but are not limited to, those that:2 <br />1. Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, <br />including all forms of Medication-Assisted Treatment (“MAT”) approved by the U.S. <br />Food and Drug Administration. <br />2. Support and reimburse evidence-based services that adhere to the American Society <br />of Addiction Medicine (“ASAM”) continuum of care for OUD and any co-occurring <br />SUD/MH conditions. <br />3. Expand telehealth to increase access to treatment for OUD and any co-occurring <br />SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and <br />other treatment and recovery support services. <br />4. Improve oversight of Opioid Treatment Programs (“OTPs”) to assure evidence-based <br />or evidence-informed practices such as adequate methadone dosing and low threshold <br />approaches to treatment. <br />5. Support mobile intervention, treatment, and recovery services, offered by qualified <br />professionals and service providers, such as peer recovery coaches, for persons with <br />OUD and any co-occurring SUD/MH conditions and for persons who have <br />experienced an opioid overdose. <br />6. Provide treatment of trauma for individuals with OUD (e.g., violence, sexual assault, <br />human trafficking, or adverse childhood experiences) and family members (e.g., <br />surviving family members after an overdose or overdose fatality), and training of <br />health care personnel to identify and address such trauma. <br />7. Support evidence-based withdrawal management services for people with OUD and <br />any co-occurring mental health conditions. <br /> <br />2 As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for <br />new or existing programs.
The URL can be used to link to this page
Your browser does not support the video tag.